全文获取类型
收费全文 | 22588篇 |
免费 | 1669篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 225篇 |
儿科学 | 888篇 |
妇产科学 | 771篇 |
基础医学 | 2894篇 |
口腔科学 | 235篇 |
临床医学 | 2923篇 |
内科学 | 3884篇 |
皮肤病学 | 514篇 |
神经病学 | 2246篇 |
特种医学 | 438篇 |
外科学 | 2299篇 |
综合类 | 239篇 |
一般理论 | 36篇 |
预防医学 | 3217篇 |
眼科学 | 296篇 |
药学 | 1471篇 |
中国医学 | 21篇 |
肿瘤学 | 1722篇 |
出版年
2024年 | 32篇 |
2023年 | 284篇 |
2022年 | 357篇 |
2021年 | 784篇 |
2020年 | 483篇 |
2019年 | 806篇 |
2018年 | 826篇 |
2017年 | 617篇 |
2016年 | 644篇 |
2015年 | 681篇 |
2014年 | 933篇 |
2013年 | 1346篇 |
2012年 | 2044篇 |
2011年 | 2171篇 |
2010年 | 1114篇 |
2009年 | 998篇 |
2008年 | 1580篇 |
2007年 | 1677篇 |
2006年 | 1511篇 |
2005年 | 1318篇 |
2004年 | 1158篇 |
2003年 | 1028篇 |
2002年 | 916篇 |
2001年 | 112篇 |
2000年 | 56篇 |
1999年 | 86篇 |
1998年 | 151篇 |
1997年 | 85篇 |
1996年 | 70篇 |
1995年 | 73篇 |
1994年 | 53篇 |
1993年 | 38篇 |
1992年 | 28篇 |
1991年 | 24篇 |
1990年 | 21篇 |
1989年 | 15篇 |
1988年 | 24篇 |
1987年 | 22篇 |
1986年 | 24篇 |
1985年 | 16篇 |
1984年 | 16篇 |
1983年 | 14篇 |
1982年 | 17篇 |
1981年 | 11篇 |
1980年 | 9篇 |
1979年 | 10篇 |
1978年 | 3篇 |
1976年 | 3篇 |
1974年 | 8篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
12.
Targeted silencing of disease-associated genes by synthetic short interfering RNA (siRNA) holds considerable promise as a novel therapeutic strategy. However, unmodified siRNA can be potent triggers of the innate immune response, particularly when associated with delivery vehicles that facilitate intracellular uptake. This represents a significant barrier to the therapeutic development of siRNA due to toxicity and off-target gene effects associated with this inflammatory response. Here we show that immune stimulation by synthetic siRNA can be completely abrogated by selective incorporation of 2'-O-methyl (2'OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex. These noninflammatory siRNA, containing less than 20% modified nucleotides, can be readily generated without disrupting their gene-silencing activity. We show that, coupled with an effective systemic delivery vehicle, 2'OMe-modified siRNA targeting apolipoprotein B (apoB) can mediate potent silencing of its target mRNA, causing significant decreases in serum apoB and cholesterol. This is achieved at therapeutically viable siRNA doses without cytokine induction, toxicity, or off-target effects associated with the use of unmodified siRNA. This approach to siRNA design and delivery should prove widely applicable and represents an important step in advancing synthetic siRNA into a broad range of therapeutic areas. 相似文献
13.
Edyta C Pirog Rebecca N Baergen Robert A Soslow Diane Tam Amy E DeMattia Yao-Tseng Chen Christina Isacson 《The American journal of surgical pathology》2002,26(1):70-75
There is considerable interobserver variation in the diagnosis of low-grade squamous intraepithelial lesion that involves mature squamous epithelium. Our aim was to evaluate the utility of MIB-1 immunostaining as an adjunct test to increase diagnostic accuracy. Consecutive cervical biopsies originally diagnosed as normal (n = 26) or low-grade squamous intraepithelial lesion (n = 23) were reviewed by three pathologists to obtain a consensus diagnosis. MIB-1 immunostaining was performed, and positive staining was defined as a cluster of at least two stained nuclei in the upper two thirds of the epithelial thickness. Human papillomavirus (HPV) DNA detection was performed using a polymerase chain reaction assay. All cases were subsequently reclassified as low-grade squamous intraepithelial lesion (LSIL) or normal (NL) when two or three of three gold standard criteria were satisfied (LSIL gold standard criteria = consensus diagnosis of LSIL, HPV+, MIB-1+; NL gold standard criteria = consensus diagnosis of NL, HPV-, MIB-1-). Using the gold standard diagnoses, we have identified that 14 normal cases (36%) were originally overdiagnosed as LSIL, and one LSIL case (10%) was originally underdiagnosed as normal. All MIB-1-positive cases were HPV+ and identified as LSIL in the consensus review. All MIB-1-negative cases were NL by gold standard criteria. The sensitivity (1.0) and the specificity (1.0) of MIB-1 staining for identifying LSIL were superior to the sensitivity (0.9) and the specificity (0.8) of HPV testing. In conclusion, MIB-1 is a highly sensitive and specific marker for identifying low-grade squamous intraepithelial lesion and is helpful in verifying the diagnosis of equivocal cases. 相似文献
14.
15.
Many important pharmaceutical agents, including vancomycin, bleomycin, cyclosporin, and several antibiotics, are produced by non‐ribosomal peptide synthetase (NRPS) enzymes in microorganisms. The NRPS pathway produces an extensive library of products using multienzyme complexes acting in an assembly‐line fashion. Engineering an NRPS system to produce an even greater variety of products, some of which may also have beneficial therapeutic value, would be an enormous advantage. Several approaches have been successful in generating novel NRPS products: mutational biosynthesis during which nonnatural substrates are fed to an organism; domain and module swapping between different species to generate hybrid enzymes; and rational site‐directed mutagenesis, based either on phylogeny or computational prediction, intended to switch substrate specificity and produce altered products. This review will highlight the progress in these areas and describe research in the future that will extend the capacity for re‐engineering NRPS systems. Drug Dev. Res. 66:9–18, 2006. © 2006 Wiley‐Liss, Inc. 相似文献
16.
17.
Amy Paul-Ward Gary Kielhofner Brent Braveman Mara Levin 《The American journal of occupational therapy》2005,59(5):540-545
The purpose of this study was to identify perceived barriers to independent community living and employment among clients and staff members in a transitional living facility for persons with AIDS. This qualitative study used focus groups to collect these perceptions from staff members (N = 21) and clients (N = 16). Whereas staff identified both systemic and personal barriers, clients only identified systemic barriers. These findings suggest that both clients and staff recognize the types of environmental barriers to participation that have been identified by disability scholars. The findings also underscore a consequential gap between clients' exclusive emphasis on environmental barriers and staff emphasis on clients' personal barriers that impact upon participation. 相似文献
18.
19.
Sheela R Geraghty Barbara S Davidson Barbara B Warner Amy L Sapsford Jeanne L Ballard Betsy A List Rachel Akers Ardythe L Morrow 《Journal of human lactation》2005,21(1):59-66
Although there are well-established clinical human milk banks in the United States, there are no milk banks specifically intended to foster research on human milk. The authors' goal was to establish a milk bank with a core data set to support exploratory and hypothesis-driven studies on human milk. Donations to the Cincinnati Children's Research Human Milk Bank are accepted within the context of ongoing, hypothesis-driven research or on an ad hoc basis. Donors must give informed consent, and scientists wishing to use the samples must have Institutional review board approval for their use. Development of more research human milk banks can potentially provide resources for multidisciplinary collaboration and advance the study of human milk and lactation. 相似文献
20.